FDA Approved New High-Concentration YUSIMRY Formulation
The interchangeable biosimilar adds a new option for providers and health systems managing autoimmune care.
Updated on Sept. 28, 2026 in Healthcare
Live Poll
Do you believe the availability of more biosimilar drugs makes your own medical treatment more affordable?
The FDA approved a high-concentration, interchangeable biosimilar formulation of YUSIMRY for nine chronic autoimmune indications. Meitheal Pharmaceuticals holds exclusive U.S. commercialization rights for the adalimumab-aqvh injection.
Why it matters
The approval increases competition in the biologic medicine market, potentially expanding access to lower-cost therapies for the nine chronic autoimmune diseases covered. This regulatory shift provides healthcare operators with additional formulary choices as biosimilar adoption grows.
Meitheal Pharmaceuticals manages a portfolio of 80 FDA-approved products and has committed $500 million toward capital and research investments. This includes a $30 million allocation specifically for a monoclonal antibody drug substance facility.
The players
Meitheal Pharmaceuticals
A Chicago-based pharmaceutical company that manages a portfolio of 80 FDA-approved products and holds exclusive U.S. commercialization rights for YUSIMRY.
Emerge Bioscience Pte. Ltd.
A Singapore-based biotechnology firm that holds the Biologics License Application for the YUSIMRY product.
The details
As the U.S. Regulatory Agent, Meitheal Pharmaceuticals will leverage its exclusive rights to distribute this high-concentration version of the adalimumab-aqvh injection. By securing the 'interchangeable' designation, the product can be substituted for the reference drug at the pharmacy level under state regulations, streamlining the procurement and prescribing process for healthcare providers.
Timeline
July 2026: The FDA approved the Garzulys injection.
September 28, 2026: The FDA approved the high-concentration formulation of YUSIMRY.
Market Landscape
This approval follows the established federal framework for interchangeable biosimilars, which aims to reduce healthcare costs by facilitating pharmacist-level substitution. The move signals an ongoing industry shift toward high-concentration biologic formulations that aim to simplify dosing and improve adherence.
Healthcare operators and administrators should monitor their internal pharmacy formularies to assess the cost-benefit of adding this new interchangeable option. Procurement departments should review their current supply agreements to determine if this high-concentration formulation fits existing clinical workflows.
The takeaway
The addition of an interchangeable biosimilar gives health systems more leverage to negotiate costs for autoimmune treatments. Clinical managers should evaluate how this specific high-concentration product may streamline patient administration processes compared to current biologics in their inventory.
Further reading
For broader trends in drug pricing and regulatory shifts, see the latest updates in Healthcare.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you believe the availability of more biosimilar drugs makes your own medical treatment more affordable?
